Tasaru Mobility Investments

Tasaru Mobility Investments is a PIF-affiliated Saudi corporate vehicle whose primary mandate is mobility, with crossover applications in autonomous systems and edge AI that touch health logistics and remote care. The firm deploys $5M to $25M checks at Series A, Series B, and growth stages. For healthcare founders, Tasaru is an adjacent rather than core investor: relevant where the technology has clear logistics, autonomous, or edge AI components with crossover into health applications, but less so for traditional digital health or clinical software.

The firm’s natural fit is with founders building autonomous systems, edge AI, and logistics infrastructure with credible crossover into healthcare applications, including drone-based medical delivery, autonomous mobile health units, edge AI for remote diagnostics, and connected vehicle health monitoring. The right founder profile is a technical team with deep mobility or autonomous systems expertise looking to build a Saudi or GCC presence around the country’s mobility transformation. Founders building pure digital health, telemedicine, or non-mobility-adjacent clinical software are not the natural target.

Geographically, the firm’s advantage is the Saudi mobility transformation under Vision 2030, with PIF-affiliated capital flowing into autonomous, electric, and connected mobility infrastructure. For founders willing to anchor a Saudi presence (regional office, regulatory registration, partnership with Saudi mobility operators), the strategic value can be significant. For founders without GCC ambitions, the firm is not the natural partner.

The right entry path is via PIF affiliate networks, an existing portfolio founder, or a senior operator in Saudi mobility. The firm reads partner-led decks but moves at the pace of state-affiliated corporate venture; budget timeline accordingly. The pitch should lead with the mobility-health crossover thesis, the Saudi commercial wedge, and a credible plan for Saudi market entry.

Caveats. State-affiliated corporate venture introduces regulatory, political, and reporting considerations that founders with international cap tables should weigh deliberately; engage experienced regional counsel. The healthcare-specific portfolio is by design adjacent rather than core; reference calls with portfolio founders working in health-adjacent applications are essential. The check size and stage range mean Tasaru is not a fit for early-stage health-only founders; this is a Series A-and-later vehicle for crossover plays. For mobility-rooted technical founders with credible health crossover, Tasaru can be a meaningful Saudi-strategic partner; for traditional health-tech founders, look to dedicated MENA health funds.